Education
About Us
Working with TipRanks
Follow Us
Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
TVRD Stock Chart & Stats
$3.96
--
Market closed
$3.96
--
Day’s Range― - ―
52-Week Range$3.50 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.55K
Market Cap
$37.15M
Enterprise Value$16.05M
Total Cash (Recent Filing)$36.46M
Total Debt (Recent Filing)$228.00K
Price to Earnings (P/E)―
Beta0.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.62
Price to Sales (P/S)1.04
P/FCF Ratio-0.12
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$9.00Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsAnalyst notes post‑hoc analyses from the Phase 2 REVERT trial showed consistent favorable trends across imaging, biomarkers, and lung function for TTI-101 versus placebo, suggesting meaningful anti-fibrotic activity that could drive upside if replicated in confirmatory studies.
Liver Cancer Response SignalsAnalyst reports interim hepatocellular carcinoma data demonstrated notably higher response signals than typical benchmarks, indicating that positive oncology readouts could materially enhance clinical and commercial prospects.
Next-generation FormulationAnalyst highlights that the TTI-109 prodrug is designed to improve gastrointestinal tolerability and bioavailability relative to the parent compound, which could expand patient tolerability and commercial potential.
Bears Say
Research Conflicts Of InterestDisclosure indicates the covering firm maintains business relationships with companies it covers, creating potential conflicts of interest that could affect report objectivity and investor perception.
Safety And Tolerability ConcernsAnalyst flags safety signals tied to combination therapy, including gastrointestinal adverse events and higher treatment discontinuations, creating uncertainty around combination regimens and development plans.
Trial Data InterpretabilityAnalyst warns that topline efficacy from the Phase 2 REVERT trial was difficult to interpret because many patients discontinued treatment in the active arm, reducing confidence in the nominal efficacy readout.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $3.50 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $37.15M.
When is Tvardi Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tvardi Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (127.27% Upside)
$9.00 (127.27% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.48%
12-Months-Change
Fundamentals
Return on Equity
-97.61%
Trailing 12-Months
Asset Growth
-39.65%
Trailing 12-Months
Company Description
Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
TVRD Stock 12 Month Forecast
Average Price Target
$9.00
▲(127.27% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
13.09% Insiders
7.83% Mutual Funds
12.51% Other Institutional Investors
60.13% Public Companies and Individual Investors
Options Prices
Currently, No data available
---